+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

Collaboration Deals in Pharmaceuticals 2020-2025 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2020-2025

  • Report
  • September 2025
  • 950 Pages
  • Global
From
From
From
From
Arzerra - Product Thumbnail Image

Arzerra

  • Report
  • January 2019
  • 18 Pages
  • Global
From
Malignant Glioma - Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Glioma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Targeted Drug Delivery - Global Strategic Business Report - Product Thumbnail Image

Targeted Drug Delivery - Global Strategic Business Report

  • Report
  • October 2025
  • 168 Pages
  • Global
From
From
From
Immuno-Oncology - Thematic Intelligence - Product Thumbnail Image

Immuno-Oncology - Thematic Intelligence

  • Report
  • May 2023
  • 169 Pages
  • Global
From
Antibody Discovery - Global Strategic Business Report - Product Thumbnail Image

Antibody Discovery - Global Strategic Business Report

  • Report
  • October 2025
  • 224 Pages
  • Global
From
Antibody Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Antibody Therapeutics - Global Strategic Business Report

  • Report
  • October 2025
  • 577 Pages
  • Global
From
Immuno-Oncology - Thematic Research - Product Thumbnail Image

Immuno-Oncology - Thematic Research

  • Report
  • May 2022
  • 167 Pages
  • Global
From
From
Loading Indicator